Dalfampridine Withdrawn Phase 2 Trials for Vestibular Diseases / Vestibular Migraine / Migraine Disorders Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT035783544-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine